Acute Pain Market

DelveInsight’s Acute Pain market report offers comprehensive coverage of the current treatment practices, pipeline therapies, and market share of the individual drug, current and forecasted Acute Pain market size from 2018 to 2030 in the 7MM.

Some of the Key Highlights from the Acute Pain Market Report 

• As per DelveInsight estimates, the Acute Pain patient pool was 91,011,151 in the US in 2020.
• DelveInsight’s analysts discovered that patients with moderate pain accounted for the largest patient pool, followed by patients with mild pain, and those with severe pain accounted for the smallest patient pool.
• Leading companies in the Acute Pain market include Charleston Laboratories, Neumentum, Neurana Pharmaceuticals, and others. 
• Key Acute Pain therapies in the pipeline include CL-108, NTM-001, Omzya, and others. 
• Neumentum is working on NTM-001, the primary product candidate. It is an alcohol-free formulation of the potent nonsteroidal anti-inflammatory drug (NSAID) ketorolac in a pre-mixed bag designed for continuous infusion for 24 hours following surgery.

For further information related to disease, request for the sample @ Acute Pain Market Outlook 

Acute Pain Overview

Acute pain is defined as “an expected physiologic response to injurious stimuli that can become pathologic, is typically sudden in onset, time-limited, and motivates behaviours to avoid actual or potential tissue injuries.”

Acute Pain Epidemiology Segmentation

The Acute Pain report proffers epidemiological analysis for the study period 2018-30 in the 7MM segmented into:

• Acute Pain Total Patient Pool
• Acute Pain Severity-Specific Patient Pool
• Acute Pain Treatable Cases 

Acute Pain Treatment Landscape 

NSAIDs and opioids are currently recommended for Acute Pain treatment, but their overuse is a major concern that must be addressed. In the previous few years, the USFDA approved drugs such as Dsuvia (AcelRx Pharmaceuticals), Ubrogepant (Allergan), Zynrelef (Heron Therapeutics), and Olinvyk injection (Trevena) for treatment of acute pain-related conditions.

Acute Pain Market Outlook

The Acute Pain market will grow during the forecast period as a result of increased R&D activities and a larger patient pool. Pharmaceutical companies are working to develop potential therapies for acute pain in order to meet the unmet medical needs of the currently available therapeutics.

Get a detailed analysis of the market @ Acute Pain Market Analysis 

Acute Pain Pipeline Therapies and Key Companies 

• CL-108: Charleston Laboratories
• NTM-001: Neumentum
• Omzya: Neurana Pharmaceuticals

Table of Contents 

Get in touch with our business executive for Healthcare Due Diligence Services

Related Reports

Acute Ocular Pain Market 

Get a comprehensive analysis of Acute Ocular Pain pipeline therapies and key companies such as Ocular Therapeutix, Kala Pharmaceuticals, Sun Pharmaceutical, Bausch & Lomb, Formosa Pharmaceuticals, Sylentis, among others.

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Sandeep Joshi
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: www.delveinsight.com/